TY - JOUR
T1 - Safety and efficacy of endoscopic sleeve gastroplasty after liver transplantation
AU - Richter, Benjamin I.
AU - Abboud, Yazan
AU - Phansalkar, Jay
AU - Lunsford, Keri E.
AU - Tafesh, Zaid
AU - Amin, Arpit
AU - Dosh, Dhvani
AU - Al-Khazraji, Ahmed
AU - Gokturk, Suut
AU - Gaglio, Paul
AU - Hajifathalian, Kaveh
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/6
Y1 - 2025/6
N2 - Background and Aims: Obesity after liver transplantation (LT) can compromise patient outcomes. We report safety and efficacy data on endoscopic sleeve gastroplasty (ESG) after LT. Methods: This is a retrospective case series of patients who underwent ESG after LT. Results: All 5 patients underwent ESG at a median 47.3 months (interquartile range [IQR], 34.4-67.4 months) after LT. Patients were predominantly male (4/5, 80%) with median age 61 years (IQR, 51-61 years) and preoperative body mass index 38.8 kg/m2 (IQR, 37.1-42.6 kg/m2). Median follow-up after ESG was 18.8 months (IQR, 8.2-19.8 months). Median total body weight loss was 27.2% (IQR, 8.0%-30.0%) at the end of follow-up. Weight loss plateau occurred in 2 patients, with 5 postoperative adverse events in 4 patients (80%) that were mild, and none exceeded grade I on the Clavien-Dindo scale. No patient missed doses of immunosuppressive medications. Liver graft function remained stable. Conclusions: Our data support the use of ESG after LT, although more data are needed to validate our findings.
AB - Background and Aims: Obesity after liver transplantation (LT) can compromise patient outcomes. We report safety and efficacy data on endoscopic sleeve gastroplasty (ESG) after LT. Methods: This is a retrospective case series of patients who underwent ESG after LT. Results: All 5 patients underwent ESG at a median 47.3 months (interquartile range [IQR], 34.4-67.4 months) after LT. Patients were predominantly male (4/5, 80%) with median age 61 years (IQR, 51-61 years) and preoperative body mass index 38.8 kg/m2 (IQR, 37.1-42.6 kg/m2). Median follow-up after ESG was 18.8 months (IQR, 8.2-19.8 months). Median total body weight loss was 27.2% (IQR, 8.0%-30.0%) at the end of follow-up. Weight loss plateau occurred in 2 patients, with 5 postoperative adverse events in 4 patients (80%) that were mild, and none exceeded grade I on the Clavien-Dindo scale. No patient missed doses of immunosuppressive medications. Liver graft function remained stable. Conclusions: Our data support the use of ESG after LT, although more data are needed to validate our findings.
UR - https://www.scopus.com/pages/publications/105004365350
UR - https://www.scopus.com/pages/publications/105004365350#tab=citedBy
U2 - 10.1016/j.igie.2025.03.013
DO - 10.1016/j.igie.2025.03.013
M3 - Article
AN - SCOPUS:105004365350
SN - 2949-7086
VL - 4
SP - 162
EP - 166
JO - iGIE
JF - iGIE
IS - 2
ER -